Get the Stockscreener App
95.76
0.23%
-0.22
Merus N V stock is traded at $95.76, with a volume of 1.69M.
It is down -0.23% in the last 24 hours and up +1.23% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$95.98
Open:
$95.9
24h Volume:
1.69M
Relative Volume:
0.75
Market Cap:
$7.26B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-24.24
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
-0.20%
1M Performance:
+1.23%
6M Performance:
+121.62%
1Y Performance:
+115.89%
1-Day Range:
$95.69
$95.96
1-Week Range:
$95.63
$96.17
52-Week Range:
$33.19
$96.28
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
95.76 | 7.28B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Aug-25-25 | Initiated | Alliance Global Partners | Buy |
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO - The Malaysian Reserve
Why Merus N.V. (2GH) stock attracts wealthy investorsWeekly Loss Report & High Conviction Trade Alerts - newser.com
Is Merus N.V. (2GH) stock supported by free cash flowQuarterly Trade Report & Weekly Momentum Picks - newser.com
Will Merus N.V. stock split again soonExit Point & Stepwise Trade Signal Guides - newser.com
Why Merus N.V. (2GH) stock could be next leader2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Will Merus N.V. stock deliver strong dividend growth2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
How Merus N.V. (2GH) stock reacts to stronger dollarBull Run & Low Drawdown Investment Ideas - newser.com
Will Merus N.V. stock reach Wall Street targetsWeekly Investment Recap & Weekly Return Optimization Plans - newser.com
Can Merus N.V. stock maintain growth trajectoryJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
Is Merus N.V. stock a buy for dividend growthPortfolio Performance Report & Stock Market Timing Techniques - newser.com
Can Merus N.V. (2GH) stock test all time highsBear Alert & Daily Price Action Insights - newser.com
What market sentiment indicators show for Merus N.V. (2GH) stock2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Will Merus N.V. stock split attract more investors2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com
Is Merus N.V. stock bottoming outMarket Performance Recap & Stock Portfolio Risk Management - newser.com
Genmab prices $2.5 billion in notes to fund Merus acquisition By Investing.com - Investing.com Australia
Will Merus N.V. stock deliver better than expected guidancePortfolio Return Summary & Low Risk Growth Stock Ideas - newser.com
Key metrics from Merus N.V.’s quarterly dataTrade Signal Summary & Capital Efficient Trading Techniques - newser.com
Can Merus N.V. (2GH) stock sustain revenue momentum2025 Market Overview & Daily Price Action Insights - newser.com
Will Merus N.V. (2GH) stock keep high P E multiplesWeekly Trading Summary & Free Weekly Watchlist of Top Performers - newser.com
How Halozyme’s ENHANZE Licensing Deal With Merus May Strengthen Royalty Pipeline for HALO Investors - simplywall.st
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):